Q-omics provides the consensus-scored MIR3163 profile across patient tissues and cancer cell-line models. MIR3163 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR3163 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MIR3163 RNA expression shows 6,385 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUSC, and STAD as cancer lineages where MIR3163 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3163 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3163 survival associations across molecular data types. MIR3163 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3163 RNA expression–survival associations across cancer types. High MIR3163 expression shows unfavorable associations in ACC, MESO, LIHC, UCEC and THCA, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR3163 RNA expression.
This table summarizes MIR3163 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3163. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3163 shows higher tumor expression in LUSC, BRCA, LUAD, HNSC and KIRP. The LUSC box plot shows higher MIR3163 RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p = .022).
This table shows molecular features associated with MIR3163 in patient tissues and cancer cell lines. In patient samples, MIR3163 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
